Clinical Trial Update: Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pembrolizumab plus axitinib as neoadjuvant therapy for locally advanced non-metastatic clear cell renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Tianjin Medical University Second Hospital | Conditions: Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma | Phase 2 | Status: UNKNOWN